Triple-negative (ER-, PR-, and HER2-) breast cancer (TNBC), a heterogeneous disease, comprises approximately 10–20% of all breast cancers [5–8] and can be further grouped into distinct subtypes by gene expression profiling [9]. This evidence concerns the gene ESR1 and breast cancer.